Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - Barron's
1. Sage Therapeutics shares rose after Biogen's acquisition proposal. 2. Biogen offered $7.22 per share for remaining Sage shares. 3. Proposal signals Biogen's confidence in Sage's pipeline. 4. Market reacted positively to potential merger news. 5. SAGE stock decrease indicates volatility ahead of final decision.